# Envoy Medical, Inc.: overview

COCH · Nasdaq · CIK 1840877 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/coch.md) · [Financials](/companies/coch/financials.md) · [Filings](/companies/coch/filings.md) · [Insiders](/companies/coch/insiders.md)

Latest reported revenue: [$51.0k](/filings/0001213900-26-086974.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-086974).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [56.0](/filings/0001213900-25-107902.md) | [42.0 d](/filings/0001213900-26-032683.md) | [46.0](/filings/0001213900-26-054209.md) | [78.0](/filings/0001213900-26-086974.md) | [42.0](/filings/0001213900-25-107902.md) | [75.0 d](/filings/0001213900-26-032683.md) | [39.0](/filings/0001213900-26-054209.md) | [51.0](/filings/0001213900-26-086974.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8878.6%)](/filings/0001213900-25-107902.md) | [(10831.0%) d](/filings/0001213900-26-032683.md) | [(11102.2%)](/filings/0001213900-26-054209.md) | [(6500.0%)](/filings/0001213900-26-086974.md) | [(13590.5%)](/filings/0001213900-25-107902.md) | [(8513.3%) d](/filings/0001213900-26-032683.md) | [(15279.5%)](/filings/0001213900-26-054209.md) | [(10919.6%)](/filings/0001213900-26-086974.md) |
| Net margin | % | [(10642.9%)](/filings/0001213900-25-107902.md) | [(10995.2%) d](/filings/0001213900-26-032683.md) | [(10865.2%)](/filings/0001213900-26-086974.md) | [(7294.9%)](/filings/0001213900-26-086974.md) | [(15433.3%)](/filings/0001213900-25-107902.md) | [(8781.3%) d](/filings/0001213900-26-032683.md) | [(11156.4%)](/filings/0001213900-26-086974.md) | [(11729.4%)](/filings/0001213900-26-086974.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0001213900-25-107902.md) | not reported | [(0.29)](/filings/0001213900-26-054209.md) | [(0.32)](/filings/0001213900-26-086974.md) | [(0.35)](/filings/0001213900-25-107902.md) | not reported | [(0.08)](/filings/0001213900-26-054209.md) | [(0.07)](/filings/0001213900-26-086974.md) |
| Free cash flow | $k | [(3,780) d](/filings/0001213900-25-107902.md) | [(5,625) d](/filings/0001213900-26-032683.md) | [(3,731)](/filings/0001213900-26-054209.md) | [(4,461) d](/filings/0001213900-26-086974.md) | [(4,331) d](/filings/0001213900-25-107902.md) | [(5,857) d](/filings/0001213900-26-032683.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.2](/filings/0001213900-24-028894.md) | [0.3](/filings/0001013762-25-004299.md) | [0.2](/filings/0001213900-26-032683.md) | [0.2](/filings/0001213900-26-032683.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(3673.4%)](/filings/0001213900-24-028894.md) | [(5809.8%)](/filings/0001013762-25-004299.md) | [(8558.2%)](/filings/0001213900-26-032683.md) | [(9240.7%)](/filings/0001213900-26-032683.md) |
| Net margin | % | not reported | [(6718.6%)](/filings/0001213900-24-028894.md) | [(9469.0%)](/filings/0001013762-25-004299.md) | [(9242.2%)](/filings/0001213900-26-032683.md) | [(9857.3%)](/filings/0001213900-26-032683.md) |
| Diluted EPS | $ per share | not reported | [(1.57)](/filings/0001213900-24-028894.md) | [(2.54)](/filings/0001013762-25-004299.md) | [(1.49)](/filings/0001213900-26-032683.md) | [(1.23)](/filings/0001213900-26-032683.md) |
| Free cash flow | $m | not reported | [(9.0)](/filings/0001213900-24-028894.md) | [(17.2)](/filings/0001013762-25-004299.md) | [(18.9)](/filings/0001213900-26-032683.md) | [(18.4)](/filings/0001213900-26-032683.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/coch/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $6.0m | 7,650,000 |  | Unchanged |
| [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $6.0m | 7,650,000 |  | Unchanged |
| [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $5.0m | 6,250,000 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $697.1k | 880,214 |  | Reduced −1,458 |
| [DSG Capital Advisors, LLC](/funds/2060765.md) | 2026-06-30 | $474.2k | 625,000 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $429.1k | 541,729 |  | Added +19,905 |
| [Focus Partners Wealth](/funds/1542153.md) | 2026-06-30 | $336.8k | 425,310 |  | Added +212,655 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $235.0k | 296,679 |  | Added +1,958 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $151.1k | 190,838 |  | Added +120,379 |
| [Arcus Capital Partners, LLC](/funds/1651960.md) | 2026-06-30 | $148.6k | 187,573 |  | Unchanged |

## Recent filings

[All 325 filings](/companies/coch/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 16:30 ET | [8-K](/filings/0001213900-26-110266.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-110266 |
| 2026-10-07 | 09:00 ET | [8-K](/filings/0001213900-26-107434.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-107434 |
| 2026-08-31 | 16:30 ET | [DEF 14A](/filings/0001213900-26-095756.md) | Proxy statement, period 2026-10-12 | 0001213900-26-095756 |
| 2026-08-27 | 17:29 ET | [8-K](/filings/0001213900-26-094447.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-094447 |
| 2026-08-10 | 16:01 ET | [8-K](/filings/0001213900-26-087221.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001213900-26-087221 |
| 2026-08-10 | 08:31 ET | [10-Q](/filings/0001213900-26-086974.md) | Quarterly report, period 2026-06-30 | 0001213900-26-086974 |
| 2026-06-30 | 16:00 ET | [8-K](/filings/0001213900-26-073659.md) | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-073659 |
| 2026-06-25 | 16:01 ET | [8-K](/filings/0001213900-26-072033.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-072033 |
| 2026-05-22 | 16:05 ET | [8-K](/filings/0001213900-26-060556.md) | 3.01 Delisting notice | 0001213900-26-060556 |
| 2026-05-18 | 16:05 ET | [8-K](/filings/0001213900-26-058429.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-058429 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-032683.md), filed Mar 23, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4dcc3afe-e1e9-4006-8083-07f73e25ea71)

## About the filer

- CIK: 1840877
- Tickers: COCH, COCHW
- Exchange: Nasdaq
- SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
- State of incorporation: not reported
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 08:41 ET. No prices; not investment advice.